Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus CIPROFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOXACIN versus CIPROFLOXACIN.
CINOXACIN vs CIPROFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
1 g orally twice daily for 7-14 days.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic